Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials
Related Experiment Video
Updated: Apr 15, 2026
A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
Serge Gauthier1, Jefferson Voltaire Proaño, Jianping Jia
1McGill Center for Studies in Aging, Montreal, Que., Canada.
Objective:
The aim of this study was to provide a systematic and quantitative summary of benefit and risk of Cerebrolysin in patients with mild-to-moderate Alzheimer's disease (AD) and to avoid major deficiencies of an earlier meta-analysis.
Design:
This is a meta-analysis of randomized double-blind placebo-controlled clinical trials.
Data Sources:
Trials were identified with the help of PubMed, the Cochrane Dementia Group database, the Center for Collaborative Neurosciences, and references from reviews; no language restrictions were applied.
Study Selection:
All randomized double-blind placebo-controlled studies on 30 ml/day of Cerebrolysin in mild-to-moderate AD were included.
Results:
There were 6 eligible randomized controlled trials comparing Cerebrolysin with placebo. For all studies, either individual patient data and/or published data (aggregate data) were available. Analyses were based on the odds ratio (OR) for dichotomized global clinical change and for safety criteria, on the standardized mean difference (SMD) for pooling of cognitive function, and on the Mann-Whitney statistic (MW) for multivariate analysis of 'global benefit' (combined effect of global clinical change and cognitive function). Cerebrolysin was significantly more effective than placebo at 4 weeks regarding cognitive function (4 weeks: SMD -0.40 points; 95% CI -0.66 to -0.13; p = 0.0031; 6 months: SMD -0.37 points; 95% CI -0.90 to 0.16; p = 0.1710), at 4 weeks and 6 months regarding global clinical change (4 weeks: OR 3.32; 95% CI 1.20-9.21; p = 0.0212; 6 months: OR 4.98; 95% CI 1.37-18.13; p = 0.0150), and at 4 weeks and 6 months regarding 'global benefit' (combined efficacy criteria; 4 weeks: MW 0.57, 95% CI 0.53-0.61; p = 0.0006; 6 months: MW 0.57; 95% CI 0.53-0.61; p = 0.0010). The safety aspects of Cerebrolysin were comparable to placebo.
Conclusion:
This meta-analysis provides evidence that Cerebrolysin has an overall beneficial effect and a favorable benefit-risk ratio in patients with mild-to-moderate AD. Cerebrolysin as a therapeutic agent should be considered by clinicians seeking treatment options for mild-to-moderate AD.
Insights
Cerebrolysin significantly improved cognitive function and global clinical change in patients with mild-to-moderate Alzheimer's disease (AD). This meta-analysis confirms Cerebrolysin's favorable benefit-risk profile for AD treatment.
Area of Science:
- Neurology
- Pharmacology
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Mild-to-moderate AD presents significant challenges for patients and clinicians.
- Effective therapeutic options for AD are continuously sought.
Purpose of the Study:
- To systematically summarize the benefits and risks of Cerebrolysin in mild-to-moderate AD.
- To provide a quantitative analysis of Cerebrolysin's efficacy and safety.
- To address limitations of previous meta-analyses on Cerebrolysin for AD.
Main Methods:
- Meta-analysis of randomized, double-blind, placebo-controlled clinical trials.
- Inclusion of studies using 30 ml/day of Cerebrolysin in mild-to-moderate AD.
- Data sources included PubMed, Cochrane Dementia Group, and reference reviews without language restrictions.
Main Results:
- Cerebrolysin demonstrated significant improvements in cognitive function at 4 weeks (SMD -0.40) and global clinical change at 4 weeks (OR 3.32) and 6 months (OR 4.98).
- A combined 'global benefit' analysis showed significant positive effects at both 4 weeks (MW 0.57) and 6 months (MW 0.57).
- Safety profiles of Cerebrolysin were comparable to placebo, indicating a favorable benefit-risk ratio.
Conclusions:
- Cerebrolysin shows a significant overall beneficial effect in patients with mild-to-moderate AD.
- The drug exhibits a favorable benefit-risk ratio for treating mild-to-moderate AD.
- Clinicians should consider Cerebrolysin as a therapeutic option for mild-to-moderate AD.
More Related Videos
05:54Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016